Back to list

Neuralink

Creating a generalized brain interface to restore autonomy to those with unmet medical needs today and unlock human potential tomorrow
Health 📍 Fremont, California Founded 2016
Current Valuation
$15B
as of 2025-Q2
DECACORN

IPO Outlookprivate

Is Neuralink going public?
No. Neuralink is private and has not filed to go public. There is no S-1 on file.
What is Neuralink's valuation in 2026?
Neuralink is valued at $15B as of 2025-Q2, set by its Series E ($650M, Jun 2025). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Neuralink filed an S-1?
No public S-1 is on file for Neuralink.
Who are Neuralink's investors?
Neuralink's investors include ARK Invest, Founders Fund, Sequoia Capital, Thrive Capital, DFJ Growth, G42 and 5 more.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Neuralink develops implantable brain-computer interfaces that translate neural signals into digital actions, enabling people with paralysis to control computers and robotic devices with their thoughts. The company serves patients with severe neurological conditions including paralysis, blindness, and speech impairment. Neuralink represents a critical breakthrough in neurotechnology with FDA breakthrough designations for multiple devices and growing human clinical trials.

Company Profile

CEO
Jared Birchall
Founded
2016
HQ
Fremont, California
Employees
~600
Total Raised
$1.3B
Growth
pre-revenue, scaling to $1B by 2031
Last Round
Series E — $650M (Jun 2025)
IPO Status
none

Fundraising Status

Series E · $650M · 1y 2mo ago
noneTotal raised $1.3B

Latest Funding Round

RoundAmountDateLead InvestorPost-Money
Series E$650MJun 2025

Vertical Intelligence — Biotech / Gene Therapy

Registered trials
6
6 active · 5 recruiting
Focus areas
Tetraplegia/Tetraparesis
Quadriplegia · Quadriplegia/Tetraplegia
Latest trial start
2025-10-03
Name-verified against lead sponsor "Neuralink Corp" on ClinicalTrials.gov as of 2026-08-19. Verify on ClinicalTrials.gov ↗

Talent Signal

Hiring trend
Hiring downtrend
9% of roles posted in last 30d
Open roles
78
via greenhouse
Product-build share
77%
engineering, research, product, design
Trajectory
tightening
heavy product build — 77% of open roles are product-building functions (engineering/research/product) — 27 of 78 open roles are engineering.
Open roles trending down; no tracked executive churn.
Open roles by month
Open roles by month78Aug '26
Open roles by function
Open roles by functionEngineering27Hardware20Other15Design7Clinical & Science2Research2Data & ML2Legal & Policy1Ops & People1
product-building   go-to-market / G&A
Analog and Mixed-Signal IC Design Engineer Intern Analog IC Design and Verification EngineerAnalog IC Layout EngineerBiomedical Engineer InternChemistClinical Research Associate
Counted from Neuralink's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.

Founders & Key People

Elon MuskMax HodakBenjamin RapoportDongjin SeoPaul MerollaPhilip SabesTimothy J. GardnerTim HansonVanessa Tolosa

Investors

ARK Invest · Founders Fund · Sequoia Capital · Thrive Capital · DFJ Growth · G42 · Human Capital · Lightspeed · QIA · Valor Equity Partners · Vy Capital

Products

  • Telepathy brain-computer interface
  • Blindsight visual prosthesis
  • N1 Link implantable brain chip
  • R1 Robot surgical system
  • Neuralink Application software
  • PRIME Study clinical trial program

Competitors

Synchron · Paradromics · Precision Neuroscience · Blackrock Neurotech · Science Corporation
Brain-Computer InterfaceMedical DeviceNeurotechnologyDeep TechDecacorn
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2025-Q2. Refreshed quarterly.